Arbutus Biopharma Corp reports results for the quarter ended in December - Earnings Summary

Arbutus Biopharma

29/02/2024 15:39

* Arbutus Biopharma Corp  ABUS.OQ  reported a quarterly
adjusted
loss of 12 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -14 cents.  The mean expectation of
five analysts for the quarter was for a loss of 12 cents per
share. Wall Street expected results to range from -13 cents
to -10 cents per share.
    * Revenue fell 65.7% to $2.15 million from a year ago;
analysts
expected $4.79 million. 
    * Arbutus Biopharma Corp's reported EPS for the quarter was
a loss
of 12 cents​.
    * The company reported a quarterly loss of $19.31 million.
    * Arbutus Biopharma Corp shares had risen by 15.2% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Arbutus Biopharma
Corp is $4.00 
This summary was machine generated from LSEG data February 29 at
03:38 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.12          -0.12          Met
 Sep. 30 2023      -0.11          -0.12          Missed
 Jun. 30 2023      -0.11          -0.10          Beat
 Mar. 31 2023      -0.14          -0.10          Beat